CKD-MBD · KIMS Secunderabad
Renal Osteodystrophy — Bone Disease When the Kidneys Fail
Renal osteodystrophy is the umbrella term for the bone disease that develops in patients with chronic kidney disease — encompassing a spectrum of skeletal disorders caused by the complex mineral and hormonal dysregulation that accompanies CKD. The modern term for the full syndrome is CKD-MBD (Chronic Kidney Disease — Mineral and Bone Disorder), which includes not just the bone changes but also the vascular calcification and cardiovascular consequences that the same dysregulated calcium, phosphate, PTH, vitamin D, and FGF-23 axis drives. Bone disease and vascular calcification are the two sides of the same metabolic coin in CKD — and together they account for a substantial portion of the cardiovascular mortality that makes CKD a major risk factor for heart attack and stroke.
In healthy physiology, the kidneys activate vitamin D (converting 25-OH vitamin D to 1,25-OH vitamin D — calcitriol), excrete phosphate, and respond to PTH by releasing calcium from the tubules. As CKD progresses, all three fail: phosphate accumulates (because the kidneys cannot excrete it), vitamin D activation is impaired (because the enzyme 1-alpha hydroxylase in the kidney is lost), and PTH rises compensatorily to maintain calcium (secondary hyperparathyroidism). The downstream consequences on bone are multiple and simultaneous.
The three components of renal osteodystrophy
Osteitis fibrosa cystica (high-turnover bone disease)
Driven by secondary hyperparathyroidism — excess PTH stimulates osteoclasts, causing accelerated bone resorption. The bone becomes weakened, with characteristic cystic changes and subperiosteal bone resorption (visible on X-ray at the radial aspect of the middle phalanges — pathognomonic of hyperparathyroidism). Brown tumours — localised collections of fibrous tissue replacing bone — may form in severe cases. High PTH levels (above 300 to 500 pg/ml in dialysis patients) indicate high-turnover bone disease.
Adynamic bone disease (low-turnover bone disease)
Paradoxically, over-suppression of PTH (often from excessive use of calcium-based phosphate binders, calcitriol, or dialysate calcium concentration) causes bone turnover to fall too low — adynamic bone. Low-turnover bone is brittle and fracture-prone, but without the cystic changes or subperiosteal resorption of high-PTH disease. Serum PTH below 100 pg/ml in dialysis patients may indicate adynamic bone.
Osteomalacia
Defective bone mineralisation from severe vitamin D deficiency or aluminium accumulation (historical — from aluminium-containing phosphate binders, now largely replaced). Bone pain, muscle weakness, and fractures. Histologically: excess osteoid (unmineralised bone matrix) without adequate mineralisation.
Mixed bone disease
Elements of more than one of the above — common in clinical practice where multiple mechanisms operate simultaneously.
Clinical features
Bone pain — diffuse, often poorly localised aching in the long bones, spine, and hips. Worse on weight-bearing. May be misattributed to arthritis or muscular pain.
Proximal muscle weakness — from vitamin D deficiency (vitamin D has direct effects on muscle function independent of bone).
Fractures — both spontaneous and traumatic fractures occur at increased rates in CKD. Rib fractures, hip fractures, and vertebral compression fractures are the most common.
Bone deformity — in severe untreated secondary hyperparathyroidism in children, growth plate involvement causes skeletal deformity (renal rickets).
Pruritus — elevated calcium-phosphate product (Ca × PO4) causes calcium phosphate deposition in skin and subcutaneous tissues, contributing to uraemic pruritus.
Vascular calcification — calcification of arterial walls (medial calcification — Mönckeberg type), coronary arteries, heart valves, and soft tissues. Manifests as cardiovascular disease, peripheral vascular disease, and calciphylaxis (calcium deposits in skin vessels causing skin necrosis — a serious complication).
Monitoring — the CKD-MBD blood panel
Serum phosphate
Target 0.87–1.49 mmol/L (2.7–4.6 mg/dL) · Often above 1.8 mmol/L in dialysis patients. Frequency: Every 1–3 months. Action: Dietary phosphate restriction · Phosphate binders (calcium carbonate, sevelamer, lanthanum) · Intensified dialysis.
Serum calcium
Target low-normal range in CKD (avoid hypercalcaemia). Dialysis target: normal range (2.1–2.5 mmol/L). Frequency: Every 1–3 months. Action: Adjust calcium carbonate dose · Adjust dialysate calcium concentration · Reduce calcitriol if calcium high.
Intact PTH
CKD Stage 3–5: above 70 pg/ml (1–5× upper normal) suggests secondary HPT. Dialysis: target 2–9× upper normal (150–600 pg/ml). Frequency: Every 3–6 months. Action: If high — phosphate binders, activated vitamin D (calcitriol or paricalcitol), cinacalcet. If very high (above 800) — consider parathyroidectomy.
25-OH vitamin D
Above 30 ng/ml (75 nmol/L) — replete. Frequency: Annually. Action: Cholecalciferol (native vitamin D3) supplementation for deficiency · Activated vitamin D (alfacalcidol or calcitriol) for secondary HPT management.
Alkaline phosphatase
Elevated indicates high bone turnover. Frequency: Every 3–6 months. Action: Marker of response to PTH-lowering therapy.
Treatment at KIMS
Dietary phosphate restriction
Limiting high-phosphate foods — dairy products, processed meats, cola drinks, nuts — to below 800 to 1,000 mg/day. Phosphate additives in processed foods are particularly bioavailable and should be specifically avoided. KIMS provides dietitian-guided phosphate restriction counselling to all Stage 3+ CKD patients.
Phosphate binders
Taken with meals to bind dietary phosphate in the gut before absorption. Calcium carbonate (also provides calcium supplement — useful where hypocalcaemia is present but avoided if calcium is already high). Sevelamer (non-calcium, non-aluminium — preferred where hypercalcaemia or vascular calcification is a concern). Lanthanum carbonate. Sucroferric oxyhydroxide.
Activated vitamin D (alfacalcidol, calcitriol, paricalcitol)
Suppresses PTH secretion by directly acting on the parathyroid gland. Used for secondary hyperparathyroidism. Must be used cautiously — can raise calcium and phosphate, worsening vascular calcification if these are not controlled.
Cinacalcet (calcimimetic)
Activates the calcium-sensing receptor on the parathyroid gland, suppressing PTH secretion without raising calcium or phosphate. The preferred agent for controlling secondary HPT where calcium is already elevated or where activated vitamin D has failed. Reduces the need for parathyroidectomy.
Parathyroidectomy
Surgical removal of 3.5 or all 4 parathyroid glands (with autotransplantation of a small piece into the forearm) for refractory secondary hyperparathyroidism — PTH persistently above 800 to 1,000 pg/ml despite medical management with symptoms (bone pain, fractures, calciphylaxis, pruritus, vascular calcification progression). At KIMS, parathyroidectomy for CKD-related secondary hyperparathyroidism is coordinated between the nephrology and surgical endocrinology teams.
Book a CKD Bone Disease (Renal Osteodystrophy) Assessment at KIMS
Frequently Asked Questions — Renal Osteodystrophy
The kidneys play a central role in bone health through three mechanisms that all fail in CKD. First, the kidneys activate vitamin D (converting 25-OH vitamin D to the active 1,25-OH form — calcitriol) — without the kidneys, vitamin D cannot be activated and bone mineralisation is impaired. Second, the kidneys excrete phosphate — as they fail, phosphate accumulates in the blood, lowering calcium and stimulating PTH. Third, the parathyroid glands respond to the low calcium and high phosphate by producing excess PTH (secondary hyperparathyroidism) — which drives osteoclasts to resorb bone in an attempt to release calcium into the blood.
Secondary hyperparathyroidism is the appropriate but excessive response of the parathyroid glands to the low calcium, high phosphate, and reduced vitamin D activation of CKD. The parathyroid glands enlarge and produce excess PTH in an attempt to normalise calcium — but at the cost of progressive bone resorption. Unlike primary hyperparathyroidism (where a parathyroid adenoma produces PTH autonomously regardless of calcium), secondary hyperparathyroidism is driven by the underlying metabolic disorder of CKD. When the underlying stimulus (phosphate, low vitamin D, low calcium) is corrected — by dialysis, phosphate binders, and active vitamin D — PTH levels fall. However, in longstanding secondary hyperparathyroidism, the enlarged parathyroid glands may develop autonomous PTH secretion regardless of calcium (tertiary hyperparathyroidism), requiring parathyroidectomy.
The dietary focus in CKD-MBD is phosphate restriction — not calcium restriction. High-phosphate foods to limit: dairy products (milk, cheese, yoghurt — high natural phosphate), processed meats and sausages (contain phosphate additives — the most bioavailable form), cola and fizzy drinks (phosphoric acid — directly absorbed), nuts, seeds, and legumes. The phosphate in whole grains and plant-based proteins is less bioavailable (bound as phytate) than the phosphate in animal proteins and food additives. A KIMS renal dietitian provides individualised phosphate restriction guidance based on the patient's CKD stage, phosphate level, and dietary preferences.
Kidney transplant significantly improves CKD-MBD — the restored kidney activates vitamin D, excretes phosphate, and eliminates the stimulus for secondary hyperparathyroidism. PTH typically falls progressively after transplant. However, bone disease does not resolve immediately — established bone changes take 12 to 24 months to improve. Post-transplant, new bone challenges emerge: corticosteroids used for immunosuppression cause steroid-induced osteoporosis, and calciphylaxis may paradoxically worsen in the early post-transplant period from hypercalcaemia as PTH remains elevated initially. Bone density monitoring and vitamin D supplementation are part of the standard KIMS post-transplant protocol.
KIMS Secunderabad — Dr. V. S. Reddy (Senior Consultant Nephrologist, transplant programme), CKD-MBD blood panel monitoring, renal dietitian phosphate counselling, sevelamer and lanthanum protocols, cinacalcet and paricalcitol for secondary hyperparathyroidism, parathyroidectomy coordination, DEXA bone density scanning, post-transplant bone health management. NABH and NABL accredited. Call 040-4488-5000.